MAP2K7 and gastric cancer: S100A2 acts as a tumor suppressor in gastric cancer, and it suppresses the extracellular-signal-regulated kinase (ERK) and mitogen-activated protein kinase (MAPK)/ERK kinase (MEK) signalling pathway, which is essential for the development of gastric cancer.